Biotech entity
Piyush Goyal is most often covered alongside Bharat Health Global Expo 2026, which appears in 2 of these 4 stories. That works out to roughly 0.7 stories per week across a 39-day span. The busiest single day carried 2. The clearest coverage concentration is pharma: 3 of 4 stories, with the rest divided among 1 other category.
Last mentioned: Sep 12, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Piyush Goyal is most often covered alongside Bharat Health Global Expo 2026, which appears in 2 of these 4 stories. That works out to roughly 0.7 stories per week across a 39-day span. The busiest single day carried 2. The clearest coverage concentration is pharma: 3 of 4 stories, with the rest divided among 1 other category. Source depth averages 2.3 original sources per story, versus 2.3 across the same-window beat baseline. At 5.5, the average consequence score sits below the same-window beat average of 5.6. We currently track 4 Biotech stories that mention Piyush Goyal, published between July 31, 2026 and September 7, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 161 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Piyush Goyal. Shared-story counts are live from our verified record — not editorial picks.
Union Commerce Minister Piyush Goyal urged India's pharma sector to move beyond generics into biosimilars, biotech, and patented R&D. Biotech and pharma executives should watch for regulatory changes around clinical trials, IP, and convergence with developed markets.
Source: asiabulletin.com · (in)
For biotech and pharma professionals, Piyush Goyal's speech signals a policy pivot from generics to innovation. The minister explicitly called for leadership in R&D, new molecular entities, and biotechnology, while acknowledging past API/KSM losses. This may reshape funding and regulatory priorities for Indian drug developers.
Source: ianslive.in · prokerala.com
Meiji Seika Pharma will transfer manufacturing technology for its Japanese encephalitis vaccine, developed and marketed by KM Biologics in Japan, to Serum Institute of India. SII engineers have already visited Japan, and the Indian firm expects to file for regulatory approval as early as 2027.
Source: news.webindia123.com · aninews.in
At Bharat Innovates 2026 in Nice, Union Minister Piyush Goyal committed the entire second edition of India's Startup Fund of Funds to deep tech, including medtech and healthcare. The move promises a major boost for Indian biotech startups, with 3,000 innovators invited to shape policy and access global markets through Free Trade Agreements. For biotech founders, this signals unprecedented government backing and a direct channel to influence the funding and regulatory landscape.
Source: calcuttanews.net · aninews.in
Piyush Goyal is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
